Plain English Summary
Background and study aims
Sensorineural hearing loss (SNHL) is caused by damage to the hair cells lining the inner ear. The hair cells in the inner ear play an important role in transmitting sounds to the brain. Up until now, damage to the inner ear hair cells has been considered irreversible. Once hair cells become damaged, they will remain damaged throughout a person’s life. Hearing aids can be used for people with hearing loss to amplify sounds to make it easier for damaged hair cells to detect them but there is currently no cure. Recently, scientists have made discoveries in animals which show that it is possible to regrow hair cells, and potentially restore hearing loss, using a medication known as a gamma secretase inhibitor. The aim of this study is to test a new drug that may be able to treat sensorineural hearing loss (SNHL).
Who can participate?
Adults aged 18 to 80 who have hearing loss.
What does the study involve?
This study involves two parts. In the first part of the study, participants have three treatments of LY 3056480 injected into one ear. At the first treatment visit, participants attend the hospital and receive a 25 μg dose and are asked to stay overnight to test their hearing, balance and health. Participants are followed up by telephone the next day and then six days after the treatment they return to the hospital to repeat the tests. The second treatment visit, participants receive another dose. Participants are allowed to go home after and receive follow up telephone call one day after treatment. They are asked to return to the hospital six days after the return to repeat the tests. The third treatment visit, participants receive another dose. Participants are allowed to go home after and receive follow up telephone call one day after treatment. They are asked to return to the hospital six days after the return to repeat the tests. If participants find their maximum tolerated dose (MTD) then they are enrolled in the second part of the study. Participants are then randomly allocated to receive either the MTD or one dose below, using the same process as the first part of the study.
What are the possible benefits and risks of participating?
Participants may benefit from improvements to their hearing loss symptoms. There are always risks involved in testing new drug treatments in people. As this is the first time the drug is tested in humans, it is not clear what the exact risks will be, but specific functions like hearing and tinnitus, balance, facial nerve function and taste are monitored closely for any changes throughout the study. In addition, side effects occurring elsewhere, including the site of the injection in the ear, the heart, kidneys and liver and blood are checked.
Where is the study run from?
Ear Nose and Throat Hospital UCL (UK)
When is the study starting and how long is it expected to run for?
July 2016 to July 2017
Who is funding the study?
Horizon 2020 Framework Programme (Belgium)
Who is the main contact?
Mr Rolf Jan Rutten
Mr Rolf Jan Rutten
+31 6 46767255
A Phase I/II multiple ascending dose open-label safety and efficacy study of the Notch Inhibitor LY3056480 in patients with mild to moderate SNHL
LY3056480 may induce transdifferentiation of supporting cells into inner-ear hair cells and lead to a subsequent improvement of hearing in patients with sensorineural hearing loss (SNHL).
London - Central REC Committee, 25/10/2017, ref: 17/LO/0632
Part 1: Open-label single centre multiple ascending dose safety study
Part 2: Multi-centre efficacy randomised study
Primary study design
Secondary study design
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Sensorineural hearing loss
In the first part of this study, participants have three treatment visits where they receive three injections of LY3056480 administered trans-tympanically into one ear. This is done using a location anaesthetic cream to numb the ear drum. The drug is injected through the eardrum using a syringe. This injection takes approximately ten minutes. This is done in ascending dose cohort of 25μg, 125μg, 200μg, and 250μg applied in 500 μl. The maximum dose is determined by the maximum volume that can be administered in the inner ear and the maximum solubility in the formulation. For the selected starting dose a safety factor of ten is applied, starting with 10% of the maximum dose. Participants are asked to lay till with their head in a set position for one hour after receiving their injections.
At the first visit, participants receive a dosage of 25μg and stay overnight at the hospital in order to monitor their hearing, balance, and general health to assess the safety of the drug. Participants are monitored routinely for their blood pressure, heart rate, and oral temperature. After participants are assessed for their hearing, balance and general health they are discharged. Participants then receive a telephone call the day after the first study visit to check how they are feeling. Six days after the first treatment visit, participants return to the hospital to repeat the tests.
The second visit occurs seven days after the first visit. Participants return to the hospital and the injection is repeated (25μg). Participants are able to go home after they are assessed for hearing balance and general health. Participants receive a telephone call one day after treatment to see how they are feeling. Participants then return to the hospital six days after their second visit for a safety visit, which repeats some of the assessments.
The third study visit occurs seven days after the second study visit. Participants return to the hospital and the injection is repeated (25μg). Participants are able to go home after they are assessed for hearing balance and general health. Participants receive a telephone call one day after treatment to see how they are feeling. Participants then return to the hospital six days after their second visit for a safety visit, which repeats some of the assessments.
Participants receive two more follow up visits, six and 12 weeks after their first treatment visit. The follow up takes around half a day and assesses the safety of the new drug. The overall study takes around 14 weeks.
In the second phase of the study, participants receive the highest tolerable dose resulted from the first section of the study or one dose below the highest tolerable dose (if the Maximum Tolerated Dose MTD is reached in the first part of the study). This part is designed to establish efficacy parameters at the MTD but also allows us to possibly determine a potential dose-response effect. If the MTD is found, participants are randomly assigned to the MTD or the dose below the MTD. Injections are delivered in the same process as the first part of the study.
Primary outcome measures
1. Occurrence and severity of procedure related local and systemic AEs are measured using clinical examinations, laboratory tests and patient interviews at visit one, two and three
2. Occurrence of systemic AEs as measured by potentially clinically significant changes by ECG, vital signs, physical examinations and laboratory tests at visit one, two and three
3. Occurrence of surgical and injection sites reactions in and around the treated ear as assessed by otomicroscopy at visit one, two and three
4. Safety of the treatment is assessed using changes in hearing, facial nerve function and balance at visit one, two and three
Efficacy of local treatment is measured if an optimal dose is found in part 1.
Secondary outcome measures
1. Change in hearing is measured using Pure Tone Audiometry (PTA) (dBHL) at baseline and week 12
2. Balance is measured using several balance tests at visit one, two, and three
3. Tinnitus measured using a questionnaire at visit one, two and three
Overall trial start date
Overall trial end date
Participant inclusion criteria
1. Male or female between 18 and 80 years of age
2. A primary complaint of hearing loss of ˂ 10 years in duration, the history suggesting this hearing-loss to be of age-related, noise-induced or idiopathic origin
3. A bilateral, symmetrical (<15 dBHL difference) SNHL with a pure-tone average threshold across the frequencies 0.5, 1, 2, 4 and 8 kHz of between 25 and 60 dBHL with 2 or more frequencies less than 60 dBHL
Target number of participants
Participant exclusion criteria
1. Presenting with a primary complaint of tinnitus
2. A ‘true’ air-bone gap >15 dBHL in 3 or more contiguous frequencies between 0.5, 1, 2, 4 kHz
3. History of suspected or diagnosed genetic cause of hearing loss
4. Suspected or known diagnosis of inner ear pathology, congenital hearing loss, fluctuating hearing loss, Ménière’s disease, or secondary endolymphatic hydrops, perilymph fistula, cochlear barotrauma, autoimmune hearing loss, radiation-induced hearing loss, retro-cochlear lesion
5. Evidence of acute or chronic otitis media or otitis externa on examination; or a history of middle ear pathology and/or surgery
6. Any therapy known as ototoxic within 12 months of screening
Recruitment start date
Recruitment end date
Countries of recruitment
Germany, Greece, United Kingdom
Trial participating centre
Ear Nose and Throat Hospital UCL
330 Grays Inn Road Kings Cross
Horizon 2020 Framework Programme
EU Framework Programme for Research and Innovation H2020, Horizon 2020, H2020
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Planned publication in a high-impact peer reviewed journal.
IPD sharing plan:
The current data sharing plans for the current study are unknown and will be made available at a later date
Intention to publish date
Participant level data
To be made available at a later date
Results - basic reporting